Renal Cancer

CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. First Author: Arnaud Méjean

Conclusions:Sunitinib alone is not inferior to CN followed by sunitinib in synchronous mRCC both in intermediate and poor MSKCC risk groups. CN should not be anymore the standard of care when medical treatment is required. Clinical trial information: NCT00930033

ABSTRACT LBA3

SEE ALSO PUBLICATION IN THE NEJM

EDITORIAL NEJM - R.J. Motzer & P. Russo: Cytoreductive Nephrectomy — Patient Selection Is Key